Quotables
"That the automobile has practically reached the limit of its development is suggested by the fact that during the past year no improvements of a radical nature have been introduced."
Scientific American ; Jan. 2 edition, 1909
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 5698232 | Pharmaceutical composition for treatment of sudden deafness An interferon is administered singly or in combination with other pharmacological agents to patients with idiopathic sudden sensorineural hearing loss, whereby the patients are remarkably improved.... | 12/16/1997 |
| 5696079 | Immunologic enhancement with intermittent interleukin-2 therapy A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph ... | 12/09/1997 |
| 5676942 | Composition containing human alpha interferon species proteins and method for use thereof This invention provides alpha interferon compositions comprising one or a mixture of selected highly antiviral interferon proteins, which compositions are characterized by increased anti-viral activity. These compositions may be used therapeutically in th... | 10/14/1997 |
| 5667797 | Anti-viral composition and kit and use for treating rotavirus infection and diarrhea An anti-diarrheic product comprises a foodstuff and an anti-rotaviral agent such as human defatted fat globule membranes, the human milk macromolecular fraction, skim milk, curd, whey, the milk mucin complex, the 46 Kd app.MW glycoprotein, a polypeptide h... | 09/16/1997 |
| 5654276 | Peptides and compounds that bind to the IL-5 receptor Described are peptides and peptide mimetics that bind to and the IL-receptor. Such peptides and peptide mimetics are useful in methods for treating disorders that involve improper production of or response to IL-5 and or the production and accumulation of... | 08/05/1997 |
| 5650386 | Compositions for oral delivery of active agents Modified amino acid compounds useful for the delivery of active agents are provided. The amino acids, non-alpha-amino acids, have been modified by acylation on the amino group particularly with phenyl or cyclohexyl groups. These groups have a variety of s... | 07/22/1997 |
| 5643566 | Formulation processes for lipophilic proteins Highly stable, pharmaceutical compositions comprising a therapeutically effective amount of a biologically active recombinant lipophilic protein such as human ଲ-interferon and interleukin-2 dissolved in a non-toxic, inert, therapeutically compatible... | 07/01/1997 |
| 5643564 | Glycosylated cytokines Disclosed is a sugar-modified cytokine which ensures migration of almost all of the dose of cytokine to the liver rapidly after administration to the live body and which can be advantageously used to enhance the effect of liver disease therapy and mitigat... | 07/01/1997 |
| 5632984 | Method of treatment of macular degeneration Intraocular administration of drugs such as -2a interferon is employed in the treatment of age-related macular degeneration. Intraocular administration obviates the side effects associated with systemic administration, concentrates the drug at the ... | 05/27/1997 |
| 5632983 | Method for treating secondary immunodeficiency A method of treating cellular immune deficiency in a patient including the steps of determining the presence of a cellular immune deficiency and co-administering to the patient an effective amount of a thymic peptide combined with an effective amount of a... | 05/27/1997 |
| 5628993 | Sustained releasable parenteral pharmaceutical preparations and method of producing the same A parenteral pharmaceutical preparation comprises a matrix containing a physiologically active peptide or protein and a polyglycerol diester of a saturated fatty acid, and the matrix is in a solid form at room temperature. The molecular weight of the phys... | 05/13/1997 |
| 5624895 | Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration A method for treating and/or preventing Type I diabetes mellitus in mammals and humans by administration of at least one of the following: (i) gamma interferon, (ii) an analog of gamma interferon or (iii) an inducer of gamma interferon thereof is taught. ... | 04/29/1997 |
| 5620685 | Protecting agents from radiation hazards The present invention relates to pharmaceutical composition comprising SCF protein, IL-3 protein, GM-CSF protein and IL-6 protein. More specifically, the present invention relates to a protecting agent from radiation hazards, comprising SCF protein, IL-3 ... | 04/15/1997 |
| 5609868 | Pharmaceutical compositions comprising hybrid -interferon The present invention provides a stable aqueous solution of hybrid -Interferon which contains as the stabilizer a buffer at a pH of from 3.0 to 5.0.... | 03/11/1997 |
| 5605688 | Recombinant dog and horse type I interferons This invention relates to a process for preparing recombinant horse and dog interferons and the interferons themselves.... | 02/25/1997 |
| 5595732 | Polyethylene-protein conjugates The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immun... | 01/21/1997 |
| 5580556 | Pharmaceutical compositions containing interferons and fatty acids The use of one or more of gamma-linolenic acid, dihomo-gamma-linolenic acid and arachidonic acid for the manufacture of a medicament for use in enhancement of the anti-viral, anti-cancer or anti-inflammatory effects of interferons; the medicament containi... | 12/03/1996 |
| 5574018 | Conjugates of vitamin B12 and proteins Therapeutically useful proteins are conjugated to vitamin B12 by covalent binding at the primary hydroxyl site of the ribose moiety. The resulting conjugates are biologically active and can be formulated into pharmaceutical compositions suitabl... | 11/12/1996 |
| 5559213 | Polyethylene-protein conjugates The present invention is a physiologically active, substantially non-immunogenic water soluble polyethylene glycol protein conjugate having the same utility as the protein which forms the conjugate, without having the same properties of producing an immun... | 09/24/1996 |
| 5540923 | Interferon proteins The invention relates to a method for producing isolating and purifying trophoblast interferon proteins such as ଲ-interferons, I -interferon proteins, II -interferon proteins, and γ-interferon proteins, and to a ... | 07/30/1996 |
| 5534269 | Method of producing sustained-release preparation A method of producing a sustained-release preparation which includes permitting a water-soluble polypeptide to permeate into a biodegradable matrix in the aqueous solution. The production method of the present invention makes possible the permeation of a ... | 07/09/1996 |
| 5512453 | Activated killer monocytes and tumoricidal activity and pharmaceutical compositions The present invention discloses substantially pure, functional, human, clinical grade, activated killer monocytes (AKM) produced in suspension in polypropylene ware in a serum-free medium and a pharmaceutical composition for immunotherapy of humans, compr... | 04/30/1996 |
| 5508291 | Feline interferon Purified feline interferon polypeptides are disclosed. A synthetic plasmid in which DNA encoding protein of a feline interferon is integrated, a transformant obtainable by the transformation of a host cell by the use of the synthetic plasmid and a feline ... | 04/16/1996 |
| 5503828 | Alpha interferon composition and method for its production from human peripheral blood leukocytes This invention provides a novel improved alpha interferon composition characterized by high specific activity, a purity of greater than 95% and which upon use in humans is further characterized by a substantial reduction in side effects normally associate... | 04/02/1996 |
| 5496926 | Process of preparing a soluble LDL receptor A soluble LDL receptor protein is provided. It can be isolated from cells that have been treated with an interferon, isolated from the urine of healthy human individuals or produced by recombinant techniques. The soluble LDL receptor protein is useful in ... | 03/05/1996 |
| 5496810 | Pyrimidine deoxyribonucleoside potentiation of combination therapy based on 5-fluorouracil and interferon The applicants have discovered a method of treating malignancies which comprises administering effective amounts of 5-fluorouracil, interferon- and a compound formula (I): ##STR1## wherein R is selected is selected from the group consisting of... | 03/05/1996 |
| 5482706 | Transmucosal therapeutic composition A transmucosal therapeutic composition comprising a physiologically active peptide or protein and a cytidine nucleotide derivative is described. The above composition results in a satisfactory transmucosal absorption of physiologically active peptides or ... | 01/09/1996 |
| 5460811 | Mature human fibroblast interferon A cDNA library is constructed using mRNA from human fibroblasts induced with poly(I):poly(C). A bacterial clone containing fibroblast interferon cDNA sequences identified by hybridization to a cDNA probe synthesized using deoxyoligonucleotide primers whic... | 10/24/1995 |
| 5441734 | Metal-interferon-alpha crystals The present invention provides for crystalline zinc-interferon alfa-2 (IFN -2) having a monoclinic morphology. The present invention further provides for crystalline cobalt-IFN -2, crystalline calcium-IFN -2, and crystalline IFN ... | 08/15/1995 |
| 5431909 | Stabilization of human interferon The invention relates to methods for stabilizing human interferon, including pharmaceutical compositions useful in topical applications for the treatment of disorders such as Condyloma acuminata. Amine stabilizing agents such as primary aliphatic amines a... | 07/11/1995 |
| 5428023 | Oral delivery of biologically active substances bound to vitamin B12 or analogues thereof An orally administered complex of a drug, hormone, bio-active peptide, or immunogen with the carrier molecule, such as vitamin B12 or analogue thereof, and a method for delivering said complex to the intestine of a host vertebrate in order to deliver the ... | 06/27/1995 |
| 5391713 | Interferon purification process A process for purification of human leukocyte interferon is described. The process includes immunoaffinity chromatography, ion-exchange chromatography, and a series of precipitation and centrifugation steps.... | 02/21/1995 |
| 5382657 | Peg-interferon conjugates Substituted PEG-interferon conjugates of formulae IA and IB where PEG is linked by means of activated linking reagents of formulae IIA, IIB, or IIB-1 to an amino group in the interferon, and activated linking reagents of formulae IIA, IIB, or IIB-1. The c... | 01/17/1995 |
| 5376567 | Expression of interferon genes in Chinese hamster ovary cells DNA constructs are prepared which operably link human interferon genes, selective, eukaryotic marker genes, and promoter and expression control sequences for the expression of human interferon in Chinese hamster ovary (CHO) cells or progeny thereof. The h... | 12/27/1994 |
| 5372808 | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically ... | 12/13/1994 |
| 5366725 | Method for the treatment of cancer The carcinostatic agent of the present invention is an extract from seeds of Aeginetia indica and has interleukin-2 and interferon-γ inducing potency. As shown in FIG. 1, all of the mice, to which this extract was not given, (Ɗ) died from tumor (6 mice)... | 11/22/1994 |
| 5359030 | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same A stabilized conjugated peptide complex comprising a peptide conjugatively coupled to a polymer including lipophilic and hydrophilic moieties, wherein the peptide may for example be selected from the group consisting of insulin, calcitonin, ACTH, glucagon... | 10/25/1994 |
| 5358867 | DNA cloning and expression of an L7 protein which modulates the 2'-5' oligosynthetase and H2-K*K response to type-I interferon The gene encoding a protein (L7) which appears to be a part of the human Type I interferon receptor has been cloned and expressed by recombinant DNA techniques. The protein imparts a non-species specific enhanced responsiveness to Type I interferon to tra... | 10/25/1994 |
| 5348729 | Evaluative means for detecting inflammatory reactivity The present invention is directed to a method for testing the susceptibility of a mammal to inflammatory diseases which comprises the steps of: administering to a mammal a compound selected from the group consisting of Type 1 mineralocorticoid receptor an... | 09/20/1994 |
| 5346696 | Asialoglycoprotein - conjugated medicinal agent The present invention relates to a conjugated medicinal agent prepared by combining asialoglycoprotein with a medicine which acts specifically on the liver. The conjugated medicinal agent of the present invention has the following formula (1): P-(S)x-Gal-... | 09/13/1994 |
